Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Comment by narmacon Jan 28, 2021 10:14am
193 Views
Post# 32408578

RE:RE:RE:Delay

RE:RE:RE:Delayhummmm,,,,,,,the market is anticipating dilution,,,possibly an ugly amount of dilution ,,,,we are back to flipping a coin as to what the briefing will contain on the 4th...we do know that it will be saturated with excitement from Calgary,,,that never gets old to DMcC!!,,,when,its really all about getting a pay cheque for another year,,,,,,,,it does get old for me!,,..most likely no partner,,,,,attempting to fund thru attrition ,,,,,, definitely not the best choice ,,,but of course, the only choice at this point,,,,,most likely it will be disappointing for  those of us who are hoping to exit this god forsaken company asap.The failure of enticing a partner, if that is part of this briefing, will be offset by a burst of excitement over covid19 trial info. I certainly dont expect anything released to be supportive of share price increase,,more than likely we will have price regression,,,and pray we dont get the trial launch put off for another year or more,,,,but that is not out of the realm of possibilities,,,,,the only surprise I would get from the webcast would be a share price increase,,now that would be a surprise,,,...,,! jmo,,,all based on the history of this company coupled with the past year plus some of nothing more which can only be descrbed as inaction. Pitiable at best!
<< Previous
Bullboard Posts
Next >>